Intensive care management of patients with subarachnoid haemorrhage

Current Opinion in Anaesthesiology

Volumn 20, Issue 5, 2007, Pages 400-407

  Smith, Martin ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Complications; Outcome; Subarachnoid haemorrhage; Vasospasm

Indexed keywords

DOBUTAMINE; ENOXAPARIN; FASUDIL; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM; NIMODIPINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; SIMVASTATIN; TIRILAZAD;

ANEMIA; ANEURYSM; ANGIOGRAPHY; BRAIN VASOSPASM; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG MECHANISM; FEVER; GENE THERAPY; HEART DISEASE; HEMODILUTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERVOLEMIA; HYPONATREMIA; INTENSIVE CARE NURSING; LUNG COMPLICATION; NEUROPROTECTION; PATHOPHYSIOLOGY; PATIENT MONITORING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SUBARACHNOID HEMORRHAGE; SYMPATHETIC BLOCKING; TREATMENT PLANNING;

HUMANS; INTENSIVE CARE; MONITORING, PHYSIOLOGIC; SUBARACHNOID HEMORRHAGE; TOMOGRAPHY SCANNERS, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL; VASOSPASM, INTRACRANIAL;

EID: 34548675160     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3282efa686     Document Type: Review

References (95)

1. Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 1997; 28:660-664.
2. Mayer SA, Kreiter KT, Copeland D, et al. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology 2002; 59:1750-1758.
3. Rosen DS, Macdonald RL. Subarachnoid hemorrhage grading scales: a systematic review. Neurocrit Care 2005; 2:110-118.
4. Naval NS, Stevens RD, Mirski MA, Bhardway A. Controversies in the management of aneurysmal subarachnoid hemorrhage. Crit Care Med 2006; 34:511-524. This is an outstanding review of controversies in the management of subarachnoid haemorrhage in which the authors present rigorous evaluation of eight aspects of care.
5. Lerch C, Yonekawa Y, Muroi C, et al. Specialized neurocritical care, severity grade, and outcome of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care 2006; 5:85-92. This is an evaluation of the changing demographics of patients with aneurysmal subarchnoid haemorrhage admitted to a specialized neurocritical care unit and the impact of treatment on outcome.
6. Naidech AM, Janjua N, Kreiter KT, et al. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. Arch Neurol 2005; 62:410-416.
7. Kaptain GJ, Lanzino G, Kassell NF. Subarachnoid haemorrhage: epidemiology, risk factors, and treatment options. Drugs Aging 2000; 17:183-199.
8. van der Schaaf, I, Algra A, Wermer M, et al. Endovascular coiling versus neurosurgical clipping for patients with aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005; CD003085.
9. Molyneux A, Kerr R, Stratton I, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002; 360:1267-1274.
10. Molyneux AJ, Kerr RS, Yu LM, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005; 366:809-817.
11. Diringer MN. To clip or to coil acutely ruptured intracranial aneurysms: update on the debate. Curr Opin Crit Care 2005; 11:121-125.
12. Lee KH, Lukovits T, Friedman JA. "Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage. Neurocrit Care 2006; 4:68-76. This is a review of the pathophysiology of vasospasm and the evidence for triple-H therapy with practical recommendations for its application.
13. Sakowitz OW, Unterberg AW. Detecting and treating microvascular ischemia after subarachnoid hemorrhage. Curr Opin Crit Care 2006; 12:103-111. This is a comprehensive review of the diagnosis and treatment of cerebral ischemia after subarachnoid haemorrhage.
14. Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke 2001; 32:2012-2020.
15. Janjua N, Mayer SA. Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care 2003; 9:113-119.
16. Mocco J, Zacharia BE, Komotar RJ, Connolly ES. A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurosurg Focus 2006; 21:E9. This is an excellent review of established and potential medical therapies for cerebral vasospasm after subarachnoid haemorrhage.
17. Stein SC, Levine JM, Nagpal S, LeRoux PD. Vasospasm as the sole cause of cerebral ischemia: how strong is the evidence? Neurosurg Focus 2006; 21:E2. This is a comprehensive review presenting the evidence that vasospasm is not the sole cause of cerebral ischemia after subarachnoid haemorrhage.
18. Dernbach PD, Little JR, Jones SC, Ebrahim ZY. Altered cerebral autoregulation and CO2 reactivity after aneurysmal subarachnoid hemorrhage. Neurosurgery 1988; 22:822-826.
19. Solomon RA, Post KD, McMurtry JG. Depression of circulating blood volume in patients after subarachnoid hemorrhage: implications for the management of symptomatic vasospasm. Neurosurgery 1984; 15:354-361.
20. Lad SP, Guzman R, Kelly ME, et al. Cerebral perfusion imaging in vasospasm. Neurosurg Focus 2006; 21:E7. This is a review of the role of cerebral perfusion techniques for the early detection of vasospasm and its potential to guide treatment.
21. Takagi R, Hayashi H, Kobayashi H, et al. Three-dimensional CT angiography of intracranial vasospasm following subarachnoid haemorrhage. Neuroradiology 1998; 40:631-635.
22. Lindegaard KF. The role of transcranial Doppler in the management of patients with subarachnoid haemorrhage: a review. Acta Neurochir Suppl 1999; 72:59-71.
23. Springborg JB, Frederiksen HJ, Eskesen V, Olsen NV. Trends in monitoring patients with aneurysmal subarachnoid haemorrhage. Br J Anaesth 2005; 94:259-270.
24. Mascia L, Fedorko L, terBrugge K, et al. The accuracy of transcranial Doppler to detect vasospasm in patients with aneurysmal subarachnoid hemorrhage. Intensive Care Med 2003; 29:1088-1094.
25. Grosset DG, Straiton J, McDonald I, et al. Use of transcranial Doppler sonography to predict development of a delayed ischemic deficit after subarachnoid hemorrhage. J Neurosurg 1993; 78:183-187.
26. Lindegaard KF, Nornes H, Bakke SJ, et al. Cerebral vasospasm diagnosis by means of angiography and blood velocity measurements. Acta Neurochir (Wien) 1989; 100:12-24.
27. Kett-White R, Hutchinson PJ, Al-Rawi PG, et al. Adverse cerebral events detected after subarachnoid hemorrhage using brain oxygen and microdialysis probes. Neurosurgery 2002; 50:1213-1221.
28. Meixensberger J, Vath A, Jaeger M, et al. Monitoring of brain tissue oxygenation following severe subarachnoid hemorrhage. Neurol Res 2003; 25:445-450.
29. Sarrafzadeh AS, Sakowitz OW, Kiening KL, et al. Bedside microdialysis: a tool to monitor cerebral metabolism in subarachnoid hemorrhage patients? Crit Care Med 2002; 30:1062-1070.
30. Skjoth-Rasmussen J, Schulz M, Kristensen SR, Bjerre P. Delayed neurological deficits detected by an ischemic pattern in the extracellular cerebral metabolites in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 2004; 100:8-15.
31. Claassen J, Hirsch LJ, Frontera JA, et al. Prognostic significance of continuous EEG monitoring in patients with poor-grade subarachnoid hemorrhage. Neurocrit Care 2006; 4:103-112. This prospective study of 756 patients demonstrated that continuous EEG monitoring provides independent prognostic information after poor-grade subarachnoid haemorrhage.
32. Rivierez M, Landau-Ferey J, Grob R, et al. Value of electroencephalogram in prediction and diagnosis of vasospasm after intracranial aneurysm rupture. Acta Neurochir (Wien) 1991; 110:17-23.
33. Claassen J, Hirsch LJ, Kreiter KT, et al. Quantitative continuous EEG for detecting delayed cerebral ischemia in patients with poor-grade subarachnoid hemorrhage. Clin Neurophysiol 2004; 115:2699-2710.
34. Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg 2003; 98:978-984.
35. Mayberg MR, Batjer HH, Dacey R, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994; 25:2315-2328.
36. Sen J, Belli A, Albon H, Morgan L, et al. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage. Lancet Neurol 2003; 2:614-621.
37. Naidech AM, Drescher J, Ault ML, et al. Higher hemoglobin is associated with less cerebral infarction, poor outcome, and death after subarachnoid hemorrhage. Neurosurgery 2006; 59:775-779. This prospective study of 103 patients with SAH demonstrated that those with higher haemoglobin values have improved outcomes, suggesting that the efficacy of haemodilution and the effect of blood transfusion after SAH warrants further study.
38. Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke 2000; 31:383-391.
39. Egge A, Waterloo K, Sjoholm H, et al. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery 2001; 49:593-605.
40. Raabe A, Beck J, Keller M, et al. Relative importance of hypertension compared with hypervolemia for increasing cerebral oxygenation in patients with cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 2005; 103:974-981.
41. Joseph M, Ziadi S, Nates J, et al. Increases in cardiac output can reverse flow deficits from vasospasm independent of blood pressure: a study using xenon computed tomographic measurement of cerebral blood flow. Neurosurgery 2003; 53:1044-1051.
42. Bouma GJ, Muizelaar JP. Relationship between cardiac output and cerebral blood flow in patients with intact and with impaired autoregulation. J Neurosurg 1990; 73:368-374.
43. Shimoda M, Oda S, Tsugane R, Sato O. Intracranial complications of hypervolemic therapy in patients with a delayed ischemic deficit attributed to vasospasm. J Neurosurg 1993; 78:423-429.
44. Mindea SA, Yang BP, Bendok BR, et al. Endovascular treatment strategies for cerebral vasospasm. Neurosurg Focus 2006; 21:E13. This is a review of current evidence for endovascular treatment of vasospasm resistant to medical therapy.
45. Meyer FB. Calcium antagonists and vasospasm. Neurosurg Clin N Am 1990; 1:367-376.
46. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989; 298:636-642.
47. Rinkel GJ, Feigin VL, Algra A, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005; CD000277.
48. Westermaier T, Zausinger S, Baethmann A, Schmid-Elsaesser R. Dose finding study of intravenous magnesium sulphate in transient focal cerebral ischemia in rats. Acta Neurochir (Wien) 2005; 147:525-532.
49. Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002; 96:510-514.
50. van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 2005; 36:1011-1015.
51. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 2005; 36:2024-2026.
52. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 2005; 36:1627-1632.
53. Dorsch NW, Kassell NF, Sinkula MS. Metaanalysis of trials of tirilazad mesylate in aneurysmal SAH. Acta Neurochir Suppl 2001; 77:233-235.
54. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005; 103:9-17.
55. Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 1997; 87:746-751.
56. Thomas JE, Rosenwasser RH, Armonda RA, et al. Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. Stroke 1999; 30:1409-1416.
57. Raabe A, Zimmermann M, Setzer M, et al. Effect of intraventricular sodium nitroprusside on cerebral hemodynamics and oxygenation in poor-grade aneurysm patients with severe, medically refractory vasospasm. Neurosurgery 2002; 50:1006-1013.
58. Atalay B, Caner H, Cekinmez M, et al. Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 2006; 59:1102-1107.
59. Birk S, Kruuse C, Petersen KA, et al. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004; 24:1352-1358.
60. Zhao J, Zhou D, Guo J, et al. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 2006; 46:421-428.
61. Vijay A, Santhanam R, Katusic ZS. Genetic modification of cerebral arterial wall: implications for prevention and treatment of cerebral vasospasm. Neurol Res 2006; 28:759-768. This is a review of the potential for genetic modification of cerebral vessels as a novel and promising approach for prevention and treatment of cerebral vasospasm.
62. Polderman KH. Application of therapeutic hypothermia in the ICU: opportunities and pitfalls of a promising treatment modality. Part 1: Indications and evidence. Intensive Care Med 2004; 30:556-575.
63. Todd MM, Hindman BJ, Clarke WR, Torner JC. Mild intraoperative hypothermia during surgery for intracranial aneurysm. N Engl J Med 2005; 352:135-145.
64. Thome C, Schubert GA, Schilling L. Hypothermia as a neuroprotective strategy in subarachnoid hemorrhage: a pathophysiological review focusing on the acute phase. Neurol Res 2005; 27:229-237.
65. Tokutomi T, Miyagi T, Morimoto K, et al. Effect of hypothermia on serum electrolyte, inflammation, coagulation, and nutritional parameters in patients with severe traumatic brain injury. Neurocrit Care 2004; 1:171-182.
66. Kawada S, Kinugasa K, Meguro T, et al. Experimental study of intracisternal administration of tissue-type plasminogen activator followed by cerebrospinal fluid drainage in the ultra-early stage of subarachnoid haemorrhage. Acta Neurochir (Wien) 1999; 141:1331-1338.
67. Hamada J, Kai Y, Morioka M, et al. Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cisterna magna: a prospective randomized study. Stroke 2003; 34:2549-2554.
68. Amin-Hanjani S, Ogilvy CS, Barker FG. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A metaanalysis. Neurosurgery 2004; 54:326-334.
69. Dorhout Mees SM, Rinkel GJ, Hop JW, et al. Antiplatelet therapy in aneurysmal subarachnoid hemorrhage: a systematic review. Stroke 2003; 34:2285-2289.
70. Wurm G, Tomancok B, Nussbaumer K, et al. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg 2004; 106:97-103.
71. Siironen J, Juvela S, Varis J, et al. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. J Neurosurg 2003; 99:953-959.
72. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med 2006; 354:387-396. This is a review of the incidence, pathology, management and outcome of subarachnoid haemorrhage.
73. Wartenberg KE, Mayer SA. Medical complications after subarachnoid hemorrhage: new strategies for prevention and management. Curr Opin Crit Care 2006; 12:78-84.
74. Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med 2006; 34:617-623. This continuing medical education article reviews the incidence, nature and outcome effect of systemic complications after subarachnoid haemorrhage.
75. Solenski NJ, Haley EC, Kassell NF, et al. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med 1995; 23:1007-1017.
76. Claassen J, Vu A, Kreiter KT, et al. Effect of acute physiologic derangements on outcome after subarachnoid hemorrhage. Crit Care Med 2004; 32:832-838.
77. Lim HB, Smith M. Systemic complications after head injury: a clinical review. Anaesthesia 2007; 62:474-482. This is a comprehensive review of the aetiology, treatment and outcome effect of systemic complications after brain injury, with a focus on traumatic brain injury.
78. Masuda T, Sato K, Yamamoto S, et al. Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model. Stroke 2002; 33:1671-1676.
79. Macmillan CS, Grant IS, Andrews PJ. Pulmonary and cardiac sequelae of subarachnoid haemorrhage: time for active management? Intensive Care Med 2002; 28:1012-1023.
80. Kothavale A, Banki NM, Kopelnik A, et al. Predictors of left ventricular regional wall motion abnormalities after subarachnoid hemorrhage. Neurocrit Care 2006; 4:199-205. This study identified the prevalence of myocardial dysfunction after subarachnoid haemorrhage, quantifying independent variables for the prediction for the development of regional wall motion abnormalities.
81. Tung P, Kopelnik A, Banki N, et al. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. Stroke 2004; 35:548-551.
82. Mayer SA, Lin J, Homma S, et al. Myocardial injury and left ventricular performance after subarachnoid hemorrhage. Stroke 1999; 30:780-786.
83. Naidech AM, Kreiter KT, Janjua N, et al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation 2005; 112:2851-2856.
84. Deibert E, Barzilai B, Braverman AC, et al. Clinical significance of elevated troponin I levels in patients with nontraumatic subarachnoid hemorrhage. J Neurosurg 2003; 98:741-746.
85. Kahn JM, Caldwell EC, Deem S, et al. Acute lung injury in patients with subarachnoid hemorrhage: incidence, risk factors, and outcome. Crit Care Med 2006; 34:196-202. This was a retrospective cohort study of over 600 patients with subarachnoid haemorrhage to determine the incidence and risk factors for acute lung injury and its effect on mortality and length of ICU stay.
86. Neil-Dwyer G, Walter P, Cruickshank JM, et al. Effect of propranolol and phentolamine on myocardial necrosis after subarachnoid haemorrhage. BMJ 1978; 2:990-992.
87. Walter P, Neil-Dwyer G, Cruickshank JM. Beneficial effects of adrenergic blockade in patients with subarachnoid haemorrhage. BMJ 1982; 284:1661-1664.
88. Deehan SC, Grant IS. Haemodynamic changes in neurogenic pulmonary oedema: effect of dobutamine. Intensive Care Med 1996; 22:672-676.
89. Naidech A, Du Y, Kreiter KT, et al. Dobutamine versus milrinone after subarachnoid hemorrhage. Neurosurgery 2005; 56:21-26.
90. Fisher LA, Ko N, Miss J, et al. Hypernatremia predicts adverse cardiovascular and neurological outcomes after SAH. Neurocrit Care 2006; 5:180-185.
91. Tisdall M, Crocker M, Watkiss J, Smith M. Disturbances of sodium in critically ill adult neurologic patients: a clinical review. J Neurosurg Anesthesiol 2006; 18:57-63. This is a review of the aetiology and treatment of disorders of sodium homeostasis after brain injury.
92. Fernandez A, Schmidt JM, Claassen J, et al. Fever after subarachnoid hemorrhage: risk factors and impact on outcome. Neurology 2007; 68:1013-1019. This study of over 350 patients identified risk factors for refractory fever after subarachnoid haemorrhage and confirmed that temperature elevation has adverse effects on outcome.
93. Smith MJ, Le Roux PD, Elliott JP, Winn HR. Blood transfusion and increased risk for vasospasm and poor outcome after subarachnoid hemorrhage. J Neurosurg 2004; 101:1-7.
94. Van den BG, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005; 64:1348-1353.
95. Van den BG, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367.